Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection.

Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H.

Neuropsychiatr Dis Treat. 2014 Jun 20;10:1125-31. doi: 10.2147/NDT.S61409.

2.

Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.

Detke HC, Weiden PJ, Llorca PM, Choukour M, Watson SB, Brunner E, Ascher-Svanum H.

J Clin Psychopharmacol. 2014 Aug;34(4):426-34. doi: 10.1097/JCP.0000000000000140.

PMID:
24781441
3.

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.

Witte MM, Case MG, Schuh KJ, Ascher-Svanum H.

Curr Med Res Opin. 2012 Mar;28(3):315-23. doi: 10.1185/03007995.2012.657300.

PMID:
22236137
4.

Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.

Mitchell M, Kothare P, Bergstrom R, Zhao F, Jen KY, Walker D, Johnson J, McDonnell D.

Clin Ther. 2013 Dec;35(12):1890-908. doi: 10.1016/j.clinthera.2013.09.023.

PMID:
24184052
5.

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.

Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H.

BMC Psychiatry. 2013 Sep 16;13:224. doi: 10.1186/1471-244X-13-224.

6.

An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D.

J Clin Psychiatry. 2008 May;69(5):790-9. Erratum in: J Clin Psychiatry. 2011 Aug;72(8):1157.

PMID:
18452346
8.

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ.

Pharmacoeconomics. 2005;23(3):299-314.

PMID:
15836010
9.

Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.

Hill AL, Sun B, McDonnell DP.

Clin Schizophr Relat Psychoses. 2014 Jan;7(4):216-22. doi: 10.3371/CSRP.HISU.020813.

PMID:
23428782
10.
11.

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.

Hill AL, Sun B, Karagianis JL, Watson SB, McDonnell DP.

BMC Psychiatry. 2011 Feb 15;11:28. doi: 10.1186/1471-244X-11-28.

12.

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.

Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Montgomery W, Conley RR.

Curr Med Res Opin. 2011 Apr;27(4):713-30. doi: 10.1185/03007995.2011.554533. Review.

PMID:
21265593
13.

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.

Jones ME, Andrews JS, Faries DE, Landry J, Xu J, Detke HC, Chhabra-Khanna R, McDonnell DP.

BMC Psychiatry. 2015 Nov 13;15:278. doi: 10.1186/s12888-015-0669-5.

14.
15.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
16.

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.

Druais S, Doutriaux A, Cognet M, Godet A, Lançon C, Levy P, Samalin L, Guillon P.

Pharmacoeconomics. 2016 Apr;34(4):363-91. doi: 10.1007/s40273-015-0348-x.

17.

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.

Ascher-Svanum H, Zhao F, Detke HC, Nyhuis AW, Lawson AH, Stauffer VL, Montgomery W, Witte MM, McDonnell DP.

BMC Psychiatry. 2011 Sep 23;11:152. doi: 10.1186/1471-244X-11-152.

18.

Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.

Ciudad A, Olivares JM, Bousoño M, Gómez JC, Alvarez E.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1515-22.

PMID:
16820255
19.

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.

Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D.

Am J Psychiatry. 2010 Feb;167(2):181-9. doi: 10.1176/appi.ajp.2009.07081221.

PMID:
20008947
20.

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia.

Ascher-Svanum H, Peng X, Montgomery W, Faries DE, Lawson AH, Witte MM, Novick D, Jemiai N, Perrin E, McDonnell DP.

Eur Psychiatry. 2011 Jul-Aug;26(5):313-9. doi: 10.1016/j.eurpsy.2010.03.015.

PMID:
20621454
Items per page

Supplemental Content

Support Center